Skip to content

Study · Ex vivo tissue · rat · 2010

2 results

Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction.

Paiva MA, Gonçalves LM, Providência LA, Davidson SM, Yellon DM, Mocanu MM

Cardiovascular drugs and therapy1 Feb 2010Cited by 66 (Europe PMC)

PMID20229055 (opens in a new tab)PMCIDPMC2874156 (opens in a new tab)DOI10.1007/s10557-010-6222-3 (opens in a new tab)PepBankPUB-20229055
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In perfused rat hearts, AICAR significantly reduced infarct size to 32.3 +/- 4.8% versus control.

    In plain wordsIn lab tests on rat hearts, AICAR reduced infarct size compared with control.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseMyocardial infarct size
    Study

    ratn: not reported in source

    Perfused hearts subjected to ischaemia-reperfusion
    Comparator
    Control
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 mM · 15 min at onset of reperfusionAs given in this study (rat).

    Measurements

    Infarct size
    32.3%
    AICAR
    Reported variability
    4.8%
    AICAR infarct size

    Source sentences

    Summary
    Similarly, AICAR also induced a significant reduction in infarct size to 32.3 +/- 4.8%, an effect also abrogated by CC.
    2 context sentences
    Summary · context
    Perfused rat hearts were subjected to 35 min ischaemia and 120 min reperfusion.
    Summary · context
    Metformin (50 microM) or AICAR (0.5 mM) were added for 15 min at the onset of reperfusion alone or with Compound C (CC, 10 microM), an AMPK inhibitor.

Studies that did not test the peptide alone1

In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking AICAR (acadesine).

  1. 02LabNot a test of AICAR (acadesine) aloneEx vivo tissueEfficacy outcome

    In perfused rat hearts, Compound C abrogated the reduction in infarct size induced by AICAR.

    In plain wordsIn lab tests on rat hearts, Compound C blocked the reduction in infarct size induced by AICAR.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseCompound C blockade of infarct protection
    Study

    ratn: not reported in source

    Perfused hearts subjected to ischaemia-reperfusion
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Similarly, AICAR also induced a significant reduction in infarct size to 32.3 +/- 4.8%, an effect also abrogated by CC.
    2 context sentences
    Summary · context
    Perfused rat hearts were subjected to 35 min ischaemia and 120 min reperfusion.
    Summary · context
    Metformin (50 microM) or AICAR (0.5 mM) were added for 15 min at the onset of reperfusion alone or with Compound C (CC, 10 microM), an AMPK inhibitor.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.